Evaluations of Biomarker Status Changes between Primary and Recurrent Tumor Tissue Samples in Breast Cancer Patients

Table 4

Distribution of ER, PR, and HER2 status according to biopsied site.

Sites of biopsy	Total	Change in ER		Change in PR		Change in HER2 status
		Discordant (%)	Concordant (%)	Discordant (%)	Concordant (%)	Discordant (%)	Concordant (%)
Locoregional lesions	45	12 (26.7%)	33 (73.3%)	18 (40.0%)	27 (60.0%)	9 (20.0%)	36 (80.0%)
Metastasis lesions	22	6 (27.3%)	16 (72.7%)	8 (36.4%)	14 (63.6%)	6 (27.3%)	16 (72.7%)
Lung	8	3 (37.5%)	5 (62.5%)	2 (25.0%)	6 (75.0%)	2 (25.0%)	6 (75.0%)
Liver	4	0	4 (100%)	0	4 (100%)	1 (25.0%)	3 (75.0%)
Bone	2	1 (50%)	1 (50%)	1 (50%)	1 (50%)	0	2 (100%)
MLN	1	0	1 (100%)	1 (100%)	0	1 (100%)	0
Others	7	2 (28.6%)	5 (71.4%)	4 (57.1%)	3 (42.9%)	2 (28.6%)	5 (71.4%)

MLN: Mediastinal lymph nodes.